Tell me anti histamine drugs from pharmacology from basics to clinical

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Excellent - I have a wealth of content from Goodman & Gilman's. Now I have everything needed to write a comprehensive answer. Let me compile the full response.

Antihistamine Drugs: Basics to Clinical

Based primarily on Goodman & Gilman's The Pharmacological Basis of Therapeutics, supplemented by Stahl's Essential Psychopharmacology and Miller's Anesthesia.

1. Histamine - The Foundation

Before understanding antihistamines, you need to understand histamine itself.

Synthesis and Storage

Histamine is formed by decarboxylation of L-histidine (enzyme: histidine decarboxylase)
Stored in mast cell granules and basophil granules bound to heparin proteoglycans
Also found in enterochromaffin-like (ECL) cells of the gastric mucosa and histaminergic neurons of the CNS (tuberoammillary nucleus of the posterior hypothalamus)

Histamine Receptors

Receptor	Location	Second Messenger	Key Effect
H1	Smooth muscle, endothelium, CNS neurons, nerve endings	Gq → PLC → IP3/DAG → ↑Ca²⁺	Bronchoconstriction, itch, vasodilation via NO, allergic responses
H2	Gastric parietal cells, heart, smooth muscle	Gs → ↑cAMP	Gastric acid secretion, cardiac stimulation, vasodilation
H3	Presynaptic CNS (autoreceptor), peripheral nerves	Gi → ↓cAMP	Feedback inhibition of histamine synthesis/release; modulates other NT release
H4	Hematopoietic cells, mast cells, leukocytes	Gi → ↓cAMP	Chemotaxis, cytokine secretion, immune modulation

Pathophysiological Actions of Histamine

Triple Response of Lewis (intradermal injection):

Initial red spot - direct H1-mediated vasodilation (NO production)
Flare - axonal reflex-mediated indirect vasodilation
Wheal - ↑capillary permeability → edema

Cardiovascular: Vasodilation → ↓BP; ↑heart rate (H2); AV conduction slowing (H1); ↑contractility (H2)

Respiratory: Bronchoconstriction (H1 dominant in humans) - asthmatics are hypersensitive

GI: Gastric acid secretion via H2 on parietal cells

CNS: Promotes wakefulness, cognition, locomotion (stimulatory); suppresses appetite and convulsions (inhibitory)

Nerve endings: H1 mediates itch in epidermis; pain in dermis

2. Classification of Antihistamines

Important pharmacological note: H1 antagonists are technically inverse agonists - they reduce constitutive receptor activity AND compete with histamine. They don't just block; they reverse baseline receptor tone.

H1 Antihistamines (Anti-allergic)

Generation 1 vs Generation 2 - Key Comparison

Property	1st Generation	2nd Generation
CNS penetration	High (lipophilic)	Low (P-glycoprotein substrate)
Sedation	Marked	Minimal
Anticholinergic effects	Significant	Minimal
Duration of action	4-6 hours	12-24 hours
Selectivity	Less H1-selective	More H1-selective
Examples	Diphenhydramine, chlorpheniramine, promethazine	Cetirizine, loratadine, fexofenadine

3. First-Generation H1 Antihistamines (by Chemical Class)

A. Ethanolamines - Prototype: Diphenhydramine (Benadryl)

Strong anticholinergic + sedative effects
~50% of patients get significant somnolence
Low GI side effects
Uses: Allergic reactions, motion sickness, insomnia, anaphylaxis (adjunct), Parkinsonism (anti-muscarinic benefit)
Other members: Clemastine, dimenhydrinate (for motion sickness)

B. Ethylenediamines - Prototype: Pyrilamine (Mepyramine)

Among the most H1-selective of the first-generation drugs
Relatively weak CNS effects, but some sedation
GI side effects are common
Other members: Tripelennamine

C. Alkylamines - Prototype: Chlorpheniramine (Chlor-Trimeton)

Among the most potent H1 antagonists
Less sedation than ethanolamines - better for daytime use
More CNS stimulation side effects than other groups
Uses: Allergic rhinitis, urticaria, common cold formulations
Other members: Brompheniramine, dexchlorpheniramine (active enantiomer)

D. Piperazines (First-Generation) - Prototype: Hydroxyzine (Atarax/Vistaril)

Long-acting compound
Prominent CNS depression - contributes to antipruritic action
Uses: Skin allergies (urticaria, atopic dermatitis), anxiety, pre-operative sedation
Cyclizine and meclizine - primarily for motion sickness

E. Phenothiazines - Prototype: Promethazine (Phenergan)

Significant sedative + strong anticholinergic
Also a dopamine (D2) receptor blocker
Uses: Antiemetic (primary use), pre-operative sedation, motion sickness, adjunct to opioid analgesia
Warning: Not recommended in children under 2 years (risk of fatal respiratory depression)

F. Piperidines (First-Generation) - Prototype: Cyproheptadine (Periactin)

Uniquely has both H1 antihistamine AND 5-HT2A antiserotonin activity
Causes drowsiness + significant anticholinergic effects
Stimulates appetite (used clinically for appetite stimulation, anorexia)
Uses: Urticaria, pruritus, serotonin syndrome (5-HT2A antagonism), appetite stimulation, migraine prophylaxis

4. Second-Generation H1 Antihistamines

These agents were developed starting in the 1980s to overcome the sedation and anticholinergic liabilities of the first generation.

A. Piperidines (Second-Generation) - Loratadine, Fexofenadine, Desloratadine

Loratadine (Claritin)

Prodrug - metabolized to active desloratadine
Non-sedating, no anticholinergic effects
Poor CNS penetration (P-gp substrate)
Uses: Allergic rhinitis, chronic urticaria

Fexofenadine (Allegra)

Active metabolite of terfenadine (which was withdrawn for torsade de pointes risk)
Lacks the cardiac toxicity of terfenadine
Does not penetrate CNS
Uses: Seasonal allergic rhinitis, urticaria

Desloratadine (Clarinex)

Active metabolite of loratadine; slightly more potent
Mast cell-stabilizing + anti-inflammatory properties
Uses: Allergic rhinitis, urticaria

Historical note: Terfenadine and astemizole (early 2nd-gen) were withdrawn from the market because they blocked cardiac hERG K⁺ channels → prolonged QT → torsade de pointes. This is especially dangerous when combined with CYP3A4 inhibitors (azole antifungals, macrolide antibiotics) that increase their blood levels.

B. Piperazines (Second-Generation) - Cetirizine, Levocetirizine

Cetirizine (Zyrtec)

Metabolite of hydroxyzine
Minimal anticholinergic effects, low CNS penetration
Slightly more sedating than other 2nd-gen agents (still much less than 1st gen)
Additional mast cell-stabilizing and anti-inflammatory properties
Uses: Allergic rhinitis, chronic urticaria, atopic dermatitis

Levocetirizine (Xyzal)

Active R-enantiomer of cetirizine
~2x more potent; used at half the dose
Less sedation than racemic cetirizine
Mast cell-stabilizing properties

C. Alkylamine (Second-Generation) - Acrivastine

Derivative of triprolidine (first-gen)
Slightly more sedating than other 2nd-gen agents

D. Dibenzoxepine Tricyclic (Topical) - Olopatadine (Patanol, Pataday)

Topical H1 antagonist + mast cell stabilizer + anti-inflammatory
Available as eye drops (allergic conjunctivitis) and nasal spray (allergic rhinitis)
Minimal systemic absorption - essentially no systemic side effects

5. H2 Antihistamines (Antisecretory)

These block H2 receptors on gastric parietal cells - completely different clinical role from H1 blockers.

Drug	Notes
Cimetidine	First H2 blocker; significant CYP450 inhibitor - many drug interactions; weak anti-androgenic effects
Ranitidine	Withdrawn in 2020 (NDMA contamination concern)
Famotidine	Most potent H2 blocker; minimal drug interactions; preferred agent
Nizatidine	Similar to ranitidine; also withdrawn in many markets

Mechanism: Competitive antagonism at H2 receptors → ↓cAMP in parietal cells → ↓H⁺/K⁺-ATPase activity → ↓gastric acid secretion

Clinical uses: Peptic ulcer disease, GERD, Zollinger-Ellison (as adjunct), stress ulcer prophylaxis, dyspepsia

Note: H2 blockers have been largely superseded by PPIs (proton pump inhibitors) for acid-related disease, but still used for mild GERD and on-demand relief.

6. H3 and H4 Receptor Antagonists (Emerging)

H3 antagonists:

Pitolisant (Wakix) - FDA approved for narcolepsy (increases histamine release in CNS → promotes wakefulness)
Investigational in ADHD, Alzheimer's, obesity

H4 antagonists:

None FDA-approved yet
Promising for allergic rhinitis, asthma, atopic dermatitis, pruritus, rheumatoid arthritis

7. Pharmacokinetics Summary

Parameter	1st Generation	2nd Generation
Onset	15-30 min (oral)	1-3 hours
Duration	4-6 hours	12-24 hours
Protein binding	Moderate	High (fexofenadine lower)
Metabolism	Hepatic (CYP)	Hepatic / renal (fexofenadine - mostly renal excretion unchanged)
CNS penetration	Yes	No (P-gp efflux)

8. Clinical Uses (Consolidated)

Indication	Drug of Choice	Notes
Seasonal allergic rhinitis	Cetirizine, loratadine, fexofenadine	2nd gen preferred (non-sedating)
Chronic urticaria	Cetirizine, fexofenadine	Higher doses sometimes needed
Acute urticaria / anaphylaxis	Diphenhydramine (IV/IM)	Adjunct; epinephrine is primary
Atopic dermatitis (pruritus)	Hydroxyzine (sedating), cetirizine	Nocturnal sedation is sometimes desired
Motion sickness	Promethazine, dimenhydrinate, meclizine	Promethazine most effective
Nausea/vomiting	Promethazine	Also blocks D2
Pre-operative sedation	Promethazine, hydroxyzine
Insomnia (OTC)	Diphenhydramine, doxylamine	Short-term only; tolerance develops rapidly
Peptic ulcer / GERD	Famotidine (H2 blocker)	Usually combined with or replaced by PPI
Appetite stimulation	Cyproheptadine	5-HT2A + H1 antagonism
Serotonin syndrome	Cyproheptadine	5-HT2A antagonism
Allergic conjunctivitis	Olopatadine drops	Topical; excellent local effect
Parkinsonism	Diphenhydramine, orphenadrine	Anticholinergic mechanism
Narcolepsy	Pitolisant (H3 antagonist)	Promotes wakefulness

9. Adverse Effects

First-Generation

CNS: Sedation, impaired cognition, paradoxical excitation (especially in children)
Anticholinergic: Dry mouth, urinary retention, blurred vision, constipation, tachycardia
GI: Nausea, epigastric distress (ethylenediamines)
CV: QT prolongation risk (terfenadine, astemizole - now withdrawn)

Second-Generation

Minimal sedation (cetirizine slightly more than others)
Minimal anticholinergic
No significant QT prolongation risk at therapeutic doses
Headache, fatigue, dry mouth (mild)

H2 Blockers

Cimetidine: Gynecomastia, impotence, confusion (elderly), many drug interactions (CYP1A2, 2C9, 2D6, 3A4 inhibition)
Generally well tolerated as a class

10. Important Drug Interactions

Cimetidine inhibits multiple CYP enzymes - interacts with warfarin, phenytoin, theophylline, tricyclic antidepressants
1st-gen antihistamines + CNS depressants (alcohol, benzodiazepines, opioids) - additive sedation
CYP3A4 inhibitors (ketoconazole, erythromycin) historically raised terfenadine/astemizole levels → torsade de pointes (reason for withdrawal)
Anticholinergic additive effects with other antimuscarinic drugs

11. Special Populations

Pregnancy:

Chlorpheniramine and diphenhydramine - traditionally considered relatively safe (category B)
Loratadine and cetirizine - preferred 2nd-gen options in pregnancy

Elderly:

Avoid 1st-gen antihistamines (Beers Criteria) - risk of confusion, falls, urinary retention, constipation
Use 2nd-gen at lowest effective dose

Children:

Promethazine contraindicated <2 years (fatal respiratory depression risk)
Cetirizine and loratadine safe and approved for children ≥2 years

Renal impairment:

Fexofenadine, cetirizine, levocetirizine - dose reduction needed (renal excretion)

Quick Memory Mnemonic

"CAP FLD" for H1 antagonist classes:

C = Chlorpheniramine (alkylamine) - most potent, least sedating 1st-gen
A = Anti-muscarinic (diphenhydramine) - most sedating
P = Promethazine (phenothiazine) - antiemetic
F = Fexofenadine - no sedation, no interaction
L = Loratadine - once daily, non-sedating
D = Desloratadine/cetirizine - 2nd gen standard

- Goodman & Gilman's The Pharmacological Basis of Therapeutics (Chapter 43), pp. 880-884 - Stahl's Essential Psychopharmacology (Histamine chapter)

Explain me pancreatitis from basics to clinical along with management and treatment

Reading File

Finding Sources

Reading File

Loading Image

Here is a complete, textbook-graded guide to pancreatitis from basics to clinical management:

Pancreatitis: Basics to Clinical Management

Based on Schwartz's Principles of Surgery (11th ed.), Robbins & Kumar Basic Pathology, and Sleisenger & Fordtran's GI and Liver Disease.

Part 1: Anatomy Basics (The Foundation)

The pancreas is a retroperitoneal organ, 75-100 g, 15-20 cm long, sloping from the C-loop of the duodenum to the splenic hilum. It has four parts: head, neck, body, and tail.

The neck lies over L1-L2 - blunt trauma compresses it against the spine, causing ductal injury
The tail sits in the splenic hilum - vulnerable during splenectomy or left colectomy
The duct of Wirsung (main duct) + common bile duct join at the ampulla of Vater, draining into the duodenum
Pancreas divisum (failed ventral-dorsal fusion) is the most common congenital anomaly and a risk factor for pancreatitis

Why Doesn't the Pancreas Digest Itself Normally?

Four key protective mechanisms:

Enzymes made as inactive zymogens (trypsinogen, chymotrypsinogen, proelastase)
Zymogens stored in separate granules from lysosomal hydrolases
SPINK1 - a trypsin inhibitor inside acinar cells
Trypsin self-inactivates by cleaving itself (negative feedback loop)

Pancreatitis occurs when these protections are overwhelmed.

Part 2: Acute Pancreatitis

Definition

A reversible inflammatory disorder ranging from focal edema to widespread hemorrhagic necrosis. If the cause is removed, function returns to normal.

Incidence: 33-74 per 100,000 globally
Overall mortality: ~5%; rising to 30-50% in severe disease
80% mild and self-limiting; 20% develop severe disease

Etiology - "I GET SMASHED"

Letter	Cause	Key Details
I	Idiopathic	10-20%; many have occult genetic basis
G	Gallstones	Most common in US; impaction at ampulla of Vater
E	Ethanol	Second most common; multiple mechanisms
T	Trauma	Blunt abdominal injury to neck of pancreas
S	Steroids	Especially in children; thiazides also
M	Mumps/Infections	Coxsackievirus, CMV, Ascaris, Clonorchis
A	Autoimmune	IgG4-related autoimmune pancreatitis
S	Scorpion sting	Tityus trinitatis
H	Hypertriglyceridemia/Hypercalcemia	TG >1000 mg/dL = 5-10% of cases; hyperparathyroidism
E	ERCP	Post-ERCP pancreatitis in 5-10%
D	Drugs	Azathioprine, furosemide, estrogens, propofol

Gallstones + Alcohol together account for ~80% of all acute pancreatitis cases.

Pathophysiology

The central event is premature, intrapancreatic activation of digestive zymogens - autodigestion, as proposed by Chiari in 1896.

Fig: Pathogenesis of Acute Pancreatitis (Robbins & Kumar)

Three Initiating Pathways:

1. Duct Obstruction (gallstone, biliary sludge, tumor)

↑intraductal pressure → enzyme-rich interstitial accumulation
Lipase (secreted already active) → immediate fat necrosis
Injured tissue releases cytokines → edema → ischemia → more injury

2. Primary Acinar Cell Injury (alcohol, hypertriglyceridemia, ischemia, viruses)

Alcohol: ↑exocrine secretion + sphincter of Oddi contraction → outflow obstruction + direct toxicity; promotes protein plug formation in ducts
Hypertriglyceridemia: chylomicrons retard capillary flow → ischemia → lipase release → toxic free fatty acids
Direct viral acinar cell infection

3. Defective Intracellular Transport (metabolic injury, alcohol, duct obstruction)

Digestive proenzymes co-packaged with lysosomal hydrolases (cathepsin B)
Intracellular trypsinogen activation → lysosomal rupture → cascading enzyme release

The Trypsin Cascade - "Master Activator":

Once trypsin is activated, it activates everything else:

Other zymogens: chymotrypsin, elastase, phospholipase A2
Kinin system (via kallikrein) → vasodilation + ↑permeability
Clotting cascade (via factor XII/Hageman) → DIC
Complement system → systemic SIRS
Elastase → vessel wall destruction → hemorrhage
Phospholipase A2 → damages surfactant → ARDS
Lipase → fat necrosis → calcium soap precipitation → hypocalcemia

Morphology

Mild - Interstitial Edematous Pancreatitis:

Interstitial edema
Focal fat necrosis (yellow-white chalky deposits = calcium soaps)
Preserved architecture, no vascular injury

Severe - Acute Necrotizing Pancreatitis:

Gross specimen of severe acute hemorrhagic pancreatitis - sectioned longitudinally showing dark red-black hemorrhagic areas interspersed with yellow-white foci of fat necrosis

Fig: Acute necrotizing pancreatitis - dark hemorrhagic zones + yellow-white fat necrosis (Robbins)

Damage extends to acini, ducts, islets, and blood vessels
Peritoneal fluid: serous, brown-tinged, with fat globules
Fat necrosis can extend to omentum, mesentery, even subcutaneous fat
Histology: neutrophilic infiltration, acinar cell necrosis, vascular injury, hemorrhage

Clinical Presentation

Symptoms:

Epigastric pain - sudden, severe, constant, bores through to the back (mid-thoracic)
Nausea and vomiting (does not relieve pain - distinguishes from bowel obstruction)
Low-grade fever

Signs:

Epigastric tenderness ± guarding, rigidity
Absent or reduced bowel sounds (paralytic ileus)
Cullen's sign - periumbilical bruising (retroperitoneal hemorrhage tracking forward)
Grey Turner's sign - flank bruising (retroperitoneal hemorrhage tracking laterally)
Jaundice if gallstone obstructs CBD
Shock in severe cases (hypovolemia + vasodilation)

Investigations

Serum Enzymes:

Test	Rise	Peak	Returns to Normal	Notes
Amylase	6-12 hrs	24 hrs	3-5 days	Sensitivity ~80%, non-specific; can be normal in severe necrosis
Lipase	4-8 hrs	24 hrs	7-14 days	More sensitive + specific; preferred marker

Diagnosis: lipase or amylase >3x upper limit of normal

Other Labs:

Leukocytosis, ↑glucose, ↑BUN/Cr (hypovolemia)
↑ALT >3x = strongly suggests gallstone etiology (>95% PPV in right clinical context)
↓Ca²⁺ = saponification = severe disease / poor prognosis
↑TG if hypertriglyceridemia is cause
CRP >150 mg/L at 48 hours = marker of severity

Imaging:

Modality	Role
Ultrasound	First-line; gallstones, biliary dilation; poor pancreatic visualization due to bowel gas
CT with contrast (CECT)	Gold standard for severity; detects necrosis (enhancement failure), fluid collections, abscess
MRI/MRCP	Duct anatomy, choledocholithiasis, no radiation
ERCP	Therapeutic only; for persistent CBD stone + cholangitis
EUS	Detects microlithiasis, occult stones

Severity Scoring

Revised Atlanta Classification (2012) - Current Standard:

Grade	Criteria
Mild	No organ failure, no local complications; resolves within 1 week
Moderately Severe	Transient organ failure (<48 hrs) AND/OR local complications
Severe	Persistent organ failure (>48 hrs), single or multiorgan

Ranson's Criteria (11 factors):

At admission (GAL BUG):

G - Glucose >200 mg/dL
A - Age >55
L - LDH >350 IU/L
B - (W)BC >16,000
U - (as)T >250 IU/L (= AST)

At 48 hours (HOBBS):

H - Hematocrit drop >10%
O - (BUN rise >5 = "Oh no, kidneys")
B - Base deficit >4
B - (Ca²⁺) <8 mg/dL
S - Sequestration of fluid >6 L; PaO₂ <60 mmHg

Score	Mortality
0-2	<1%
3-4	~16%
5-6	~40%
>6	~100%

BISAP Score (≥3 = severe):

BUN >25, Impaired mental status, SIRS, Age >60, Pleural effusion

CT Severity Index (Balthazar + Necrosis score):

Score >6 = severe (mortality 17%, morbidity 92%)

Local Complications (Atlanta 2012 Definitions):

Complication	Timing	Wall	Contents	Management
Acute peripancreatic fluid collection	<4 weeks	No wall	Fluid only	Mostly resolve spontaneously
Pancreatic pseudocyst	>4 weeks	Defined wall (no epithelium)	Fluid	Observe if asymptomatic; drain if symptomatic
Acute necrotic collection	<4 weeks	No wall	Necrosis ± fluid	Antibiotics; defer intervention
Walled-off necrosis (WON)	>4 weeks	Defined wall	Necrosis ± fluid	Step-up approach if infected

Pseudocyst - lined by fibrin and granulation tissue (NOT epithelium) - develops in ~10% of acute pancreatitis cases and in chronic pancreatitis.

Systemic Complications:

ARDS - phospholipase A2 damages alveolar surfactant
AKI - hypovolemia + inflammation
DIC - trypsin activates factor XII + clotting cascade
Shock - third spacing of fluid, systemic vasodilation
Hyperglycemia - islet cell destruction
Hypocalcemia - fat saponification
Ileus, pancreatic ascites, left-sided pleural effusion

Part 3: Treatment and Management of Acute Pancreatitis

Step 1: Fluid Resuscitation (MOST IMPORTANT early intervention)

Lactated Ringer's solution preferred over normal saline (reduces SIRS in studies)
Goal: restore normal BP, heart rate, urine output >0.5 mL/kg/hr
Moderate resuscitation (avoid excessive fluid in elderly/cardiac/renal patients)
Monitor with BUN trends (rising BUN = inadequate resuscitation)

Step 2: Analgesia

IV opioids (fentanyl, hydromorphone, morphine)
Historical avoidance of morphine (sphincter of Oddi concern) is no longer clinically relevant
Epidural analgesia in severe cases

Step 3: Nutrition

Mild pancreatitis: Early oral feeding as soon as tolerated (low-fat soft diet)
Severe pancreatitis: Early enteral nutrition within 24-48 hours (nasogastric or nasojejunal tube)
Enteral > TPN: maintains gut barrier, reduces bacterial translocation, fewer infectious complications, lower cost
TPN only if enteral route is impossible

Step 4: Antibiotics

NOT routine - multiple RCTs showed no benefit for prophylactic antibiotics
Use ONLY for:
- Confirmed infected pancreatic necrosis (gas on CT or positive cultures)
- Associated cholangitis
- Other proven infections
Agent: imipenem/meropenem (best pancreatic penetration)

Step 5: Treat the Cause

Etiology	Treatment
Gallstones + cholangitis/CBD obstruction	Urgent ERCP within 24-72 hours
Gallstones (mild, resolving)	Cholecystectomy same admission or within 2-4 weeks
Alcohol	Counseling + cessation
Hypertriglyceridemia	Insulin drip ± plasmapheresis if TG >1000
Drugs	Stop offending drug
Hypercalcemia	Treat hyperparathyroidism

Step 6: Monitoring (ICU for Severe Cases)

Continuous monitoring of vitals, urine output, SpO₂
Serial labs: BUN, Cr, Ca²⁺, CBC, CRP, LFTs
Daily organ failure assessment
CECT at 48-72 hours if clinical deterioration

Management of Infected Necrosis - Step-Up Approach (Current Standard)

Antibiotics (carbapenem) + NPO + supportive care
If no improvement at 72-96 hours: percutaneous CT-guided drainage or endoscopic transluminal drainage (transgastric)
If still failing: minimally invasive necrosectomy (video-assisted retroperitoneal debridement - VARD, or endoscopic necrosectomy)
Open surgical necrosectomy - last resort; highest morbidity

Key principle: Wait until necrosis is walled off (>4 weeks) before intervention if clinically possible - margins are better defined, bleeding risk is lower.

Part 4: Chronic Pancreatitis

Definition

An irreversible, progressive inflammatory condition causing permanent destruction of exocrine parenchyma, eventually affecting endocrine tissue. Unlike acute pancreatitis, damage does not reverse.

Etiology - TIGAR-O

Toxic-metabolic: alcohol, tobacco, hypercalcemia, hypertriglyceridemia, chronic renal failure
Idiopathic: 15-25%
Genetic: PRSS1, SPINK1, CFTR mutations
Autoimmune: IgG4-related
Recurrent severe acute pancreatitis
Obstructive: pancreas divisum, strictures, tumors

Genetics of Hereditary Pancreatitis

PRSS1 gene (cationic trypsinogen, chromosome 7q35): R122H and N291 mutations = gain-of-function → trypsin cannot self-inactivate → persistent autodigestion
SPINK1 mutations: loss-of-function trypsin inhibitor → uncontrolled trypsin activity
CFTR mutations: defective bicarbonate/fluid secretion → viscous secretions → duct plugging
Autosomal dominant, 80% penetrance; presents in childhood
Lifetime pancreatic cancer risk: 40% in PRSS1 hereditary pancreatitis

Pathology

Extensive fibrosis replacing acinar tissue
Acinar atrophy → exocrine insufficiency
Islets preserved initially, then destroyed → Type 3c diabetes
Ductal calcifications (protein plugs calcify) - pathognomonic on imaging
Dilated ducts ("chain of lakes" on MRCP)

Clinical Features

Chronic epigastric pain radiating to back; worse with eating + alcohol; improves leaning forward
Steatorrhea - foul-smelling, floating, fatty stools; requires >90% exocrine destruction to manifest
Weight loss and malabsorption
Fat-soluble vitamin deficiency (A, D, E, K) → osteoporosis (Vitamin D), coagulopathy (Vitamin K)
Type 3c (pancreatogenic) diabetes - brittle, prone to hypoglycemia (lost glucagon from alpha cells too)
Jaundice (CBD stricture from fibrosis)
Episodes of acute-on-chronic exacerbations

Investigations

Amylase/lipase may be normal in burned-out disease (insufficient acinar tissue)
CT: pancreatic calcifications, ductal dilation, atrophy
MRCP: ductal irregularity, strictures, "chain of lakes"
Fecal elastase-1 <200 μg/g = exocrine insufficiency
Secretin stimulation test = gold standard for exocrine function
Glucose tolerance test for diabetes

Treatment of Chronic Pancreatitis

1. Lifestyle:

Absolute alcohol abstinence
Smoking cessation
Low-fat diet (5-6 small meals/day)

2. Pain Control:

WHO ladder: paracetamol/NSAIDs → tramadol → strong opioids
Pancreatic enzyme supplements - reduce CCK-driven pancreatic stimulation → pain relief
Pregabalin, tricyclic antidepressants - centrally-mediated pain
Celiac plexus block (EUS-guided) - temporary relief

3. Pancreatic Enzyme Replacement Therapy (PERT):

Pancrelipase (high lipase content) with every meal and snacks
Fat-soluble vitamins supplementation (A, D, E, K)
Goal: eliminate steatorrhea, restore normal nutrition

4. Diabetes (Type 3c) Management:

Insulin (usually required in advanced disease)
Avoid sulfonylureas - risk of severe hypoglycemia
Monitor carefully (brittle hypoglycemia risk)

5. Endoscopic Therapy:

Ductal stenting for dominant strictures
ESWL (extracorporeal shock wave lithotripsy) for calculi → then endoscopic stone removal
Pancreatic sphincterotomy

6. Surgery - Indications:

Intractable pain unresponsive to medical/endoscopic therapy
Duodenal or biliary obstruction
Suspicion of malignancy
Pancreatic fistula

Surgical Procedures:

Type	Procedure	Indication
Drainage	Puestow procedure (lateral pancreaticojejunostomy)	Dilated duct >6 mm
Drainage + decompression	Frey procedure (ductal drainage + head coring)	Dilated duct + head-predominant
Resection	Whipple (pancreaticoduodenectomy)	Head disease, non-dilated duct, mass
Resection	Beger (duodenum-preserving head resection)	Head disease, preserves duodenum
Resection	Distal pancreatectomy	Body/tail disease
Radical	Total pancreatectomy + islet autotransplantation (TPIAT)	Refractory hereditary pancreatitis

Summary Comparison

Feature	Acute Pancreatitis	Chronic Pancreatitis
Reversibility	Reversible	Irreversible
Most common cause	Gallstones (West)	Alcohol (West)
Pain character	Sudden, severe, boring to back	Chronic, post-meal, back radiation
Enzyme levels	Markedly elevated	May be normal (burned-out)
Exocrine insufficiency	Not usually	Yes - steatorrhea
Endocrine insufficiency	Transient hyperglycemia	Type 3c diabetes
Calcifications on CT	Rare	Yes - pathognomonic
Mortality	~5% overall; 30-50% severe	50% over 20-25 years
Cancer risk	Low	Elevated (40% in PRSS1 hereditary)

10 High-Yield Clinical Pearls

Lipase > Amylase as the diagnostic test - more specific, stays elevated longer
ALT >3x = gallstone etiology with >95% positive predictive value
Cullen + Grey Turner signs = retroperitoneal hemorrhage = necrotizing pancreatitis
Hypocalcemia = fat saponification = poor prognostic sign
ERCP in gallstone pancreatitis only if cholangitis or persistent CBD obstruction - not routine
Enteral > Parenteral nutrition in severe pancreatitis - start within 24-48 hours
No prophylactic antibiotics in acute pancreatitis - multiple RCTs showed no benefit
Step-up approach for infected necrosis; wait for walled-off necrosis (>4 weeks) before intervening
Amylase normal in burned-out chronic pancreatitis - use fecal elastase instead
PRSS1 hereditary pancreatitis = 40% lifetime risk of pancreatic cancer - long-term surveillance required

Sources:

Schwartz's Principles of Surgery, 11th ed., Chapter 33, pp. 1439-1468
Robbins & Kumar Basic Pathology, Chapter 15, pp. 640-646
Sleisenger & Fordtran's Gastrointestinal and Liver Disease

This is a shared conversation. Sign in to Orris to start your own chat.